A detailed history of Goldman Sachs Group Inc transactions in Citius Pharmaceuticals, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 37,940 shares of CTXR stock, worth $110,405. This represents 0.0% of its overall portfolio holdings.

Number of Shares
37,940
Previous 1,186,559 96.8%
Holding current value
$110,405
Previous $688,000 97.38%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$0.48 - $1.02 $551,337 - $1.17 Million
-1,148,619 Reduced 96.8%
37,940 $18,000
Q2 2024

Aug 13, 2024

BUY
$0.58 - $1.03 $637,462 - $1.13 Million
1,099,074 Added 1256.3%
1,186,559 $688,000
Q1 2024

May 15, 2024

SELL
$0.6 - $0.9 $3,043 - $4,564
-5,072 Reduced 5.48%
87,485 $78,000
Q4 2023

Feb 13, 2024

SELL
$0.65 - $0.86 $40,127 - $53,091
-61,734 Reduced 40.01%
92,557 $70,000
Q3 2023

May 14, 2024

BUY
$0.65 - $1.25 $40,127 - $77,167
61,734 Added 66.7%
154,291 $104,000
Q3 2023

Nov 14, 2023

SELL
$0.65 - $1.25 $57,304 - $110,201
-88,161 Reduced 36.36%
154,291 $104,000
Q2 2023

May 14, 2024

BUY
$1.08 - $1.65 $247,440 - $378,034
229,112 Added 1717.48%
242,452 $290,000
Q2 2023

Aug 14, 2023

BUY
$1.08 - $1.65 $261,848 - $400,045
242,452 New
242,452 $290,000
Q4 2022

May 14, 2024

SELL
$0.79 - $1.28 $164,253 - $266,132
-207,916 Reduced 93.97%
13,340 $10,000
Q4 2022

Feb 13, 2023

BUY
$0.79 - $1.28 $10,538 - $17,075
13,340 New
13,340 $10,000
Q2 2022

May 14, 2024

BUY
$0.88 - $1.87 $113,255 - $240,667
128,699 Added 139.05%
221,256 $203,000
Q2 2022

Aug 15, 2022

BUY
$0.88 - $1.87 $63,555 - $135,055
72,222 Added 48.46%
221,256 $203,000
Q1 2022

May 16, 2022

BUY
$1.38 - $1.89 $125,094 - $171,324
90,648 Added 155.26%
149,034 $267,000
Q4 2021

Feb 14, 2022

SELL
$1.51 - $2.2 $209,489 - $305,217
-138,735 Reduced 70.38%
58,386 $90,000
Q3 2021

Nov 10, 2021

BUY
$1.74 - $2.6 $342,990 - $512,514
197,121 New
197,121 $401,000

Others Institutions Holding CTXR

About Citius Pharmaceuticals, Inc.


  • Ticker CTXR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 146,130,000
  • Market Cap $425M
  • Description
  • Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic l...
More about CTXR
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.